Side Effects of Loxapine
Loxapine causes frequent extrapyramidal symptoms (tremor, rigidity, akathisia) and sedation, with a side effect profile similar to typical antipsychotics, including risks of tardive dyskinesia, neuroleptic malignant syndrome, and cardiovascular effects. 1
Neurological and Movement Disorders
Extrapyramidal Symptoms (EPS)
- Parkinsonian symptoms occur frequently, particularly during the first few days of treatment, manifesting as tremor, rigidity, excessive salivation, and masked facies 1
- Akathisia (motor restlessness) is reported relatively frequently and can be controlled by dose reduction or antiparkinson medications 1
- Acute dystonia may develop in susceptible individuals during initial treatment days, presenting as prolonged muscle contractions, neck spasms progressing to throat tightness, swallowing difficulty, breathing problems, and tongue protrusion 1
- Males and younger patients face elevated risk for acute dystonic reactions 1
- Loxapine causes a high incidence of extrapyramidal reactions comparable to phenothiazines and butyrophenones 2
- When compared to atypical antipsychotics, loxapine produces significantly more extrapyramidal adverse effects (RR 2.18,95% CI 1.6-3.1) 3
Tardive Dyskinesia
- Persistent tardive dyskinesia may appear during long-term therapy or after discontinuation, with greater risk in elderly patients on high-dose therapy, especially females 1
- The syndrome manifests as rhythmical involuntary movements of tongue, face, mouth, or jaw (tongue protrusion, cheek puffing, mouth puckering, chewing movements), sometimes accompanied by extremity movements 1
- No known effective treatment exists for tardive dyskinesia; antiparkinson agents do not alleviate symptoms 1
- Fine vermicular tongue movements may signal early syndrome development 1
Neuroleptic Malignant Syndrome (NMS)
- NMS has been reported with loxapine, presenting as altered mental status, hyperthermia, severe rigidity, and autonomic instability 1
- Risk factors include dehydration, physical exhaustion, preexisting brain disease, and concomitant psychotropic medications 4
Cardiovascular Effects
- Tachycardia, hypotension, hypertension, orthostatic hypotension, lightheadedness, and syncope have been reported 1
- Rare cases of ECG changes similar to phenothiazines have occurred, though causality with loxapine remains uncertain 1
- Tachycardia occurs frequently, especially during early treatment stages 2
Sedation and Cognitive Effects
- Sedation occurs frequently, particularly during early treatment stages 2, 3
- Drowsiness is a chief side effect, especially in elderly patients 5
Anticholinergic Effects
- Dry mouth, nasal congestion, constipation, blurred vision, urinary retention, and paralytic ileus have been reported 1
- These anticholinergic effects occur less commonly than EPS but follow patterns seen with older antipsychotics 2
Hematologic Effects
- Rarely, agranulocytosis, thrombocytopenia, and leukopenia may occur 1
Dermatologic Effects
- Dermatitis, facial edema (puffiness), pruritus, rash, alopecia, and seborrhea have been documented 1
Gastrointestinal and Hepatic Effects
- Nausea and vomiting occur in some patients 1
- Hepatocellular injury with SGOT/SGPT elevation has been reported, and rarely jaundice and/or hepatitis questionably related to loxapine 1
Endocrine and Metabolic Effects
- Weight gain or weight loss may occur 1
- Rarely, galactorrhea, amenorrhea, gynecomastia, and menstrual irregularities of uncertain etiology have been reported 1
Other Effects
- Dyspnea, ptosis, hyperpyrexia, flushed facies, headache, paresthesia, and polydipsia have been documented 1
- Precipitation of epileptic seizures can occur, similar to older antipsychotic drugs 2
- Slight increase in blood pressure has been observed in elderly patients 5
Dosing Considerations for Side Effect Management
- Most extrapyramidal symptoms are not severe and can be controlled by dose reduction or administration of antiparkinson drugs 1
- In elderly patients, therapeutic dosage range is 10-80 mg daily—approximately half that used for younger patients—which may reduce side effect burden 5